DSM-Firmenich has unleashed Glycare SK, a range of skin care ingredients powered by human milk oligosaccharide (HMO) biotechnology for skin regeneration and resilience.
HMOs are unique sugar molecules naturally present in mother's milk that programme the resilience that equips newborns to adapt, recover, and thrive.
Using precision fermentation, the company replicates the exact bioidentical structures found in mother’s milk — without any human-derived materials — enabling the benefits of HMOs to be applied in cosmetic formulations.
“By translating HMO biology into skincare, we can help activate the skin’s natural regenerative processes, strengthen the skin barrier, enhance resilience to inflammation and support smart microbiome adhesion,” said Martin Pagac Ph.D., global senior scientist at DSM-Firmenich.
The result is Glycare SK, a biotechnology range designed to support skin regeneration and resilience with targeted modulation of microbiome adhesion, offering a new approach for sensitive and stressed skin.
The range includes Glycare SK Renew, the repair specialist, supports barrier recovery and skin regeneration.
Advanced protocol clinically tested on individuals with chronic rosacea and sensitive skin it delivered a 19% reduction in TEWL versus placebo confirming barrier repair and reinforcement and 38% reduction in visible redness and erythema after eight weeks.
The ingredient also restored skin structure with 7% improvement in elasticity after 4 weeks, supported by 67% collagen I stimulation observed in vitro.
Meanwhile, Glycare SK Comfort focuses on everyday resilience for sensitive skin.
Clinical testing demonstrated 16% reduction in TEWL versus placebo after eight weeks, a 13% increase in hydration after four weeks, and a visible reduction in redness, helping prevent flare-ups.
